Drugs / CMV-specific T-cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03798301 | Feb 2020 → May 2023 | cytomegalovirus infection | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT03950414 | Sep 2019 → Jul 2022 | cytomegalovirus infection, disease related to solid organ transplantation | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03067155 | Oct 2016 → Dec 2021 | cytomegalovirus infection, hematopoietic and lymphoid system neoplasm | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT01220895 | Oct 2010 → Dec 2013 | cytomegalovirus infection | Cell Medica Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV specific T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03950414 ↗ |
| Action | Restore | “attempts have been made to restore antiviral immunity by direct infusion of CMV-specific T cells” NCT03067155 ↗ |
| Modality | Cell therapy | “adoptive cellular therapy” NCT01220895 ↗ |
| Route | Intravenous | “administered through intravenous transfusion” NCT03067155 ↗ |